



Tony Lomax : Head of Medical Physics: Paul Scherrer Institute, Switzerland

Myths and realities of range uncertainty in proton therapy

PPRIG – 2nd October 2016



The advantage of proton therapy

Simply put – protons stop...





Not only do they stop, but they stop sharply.



Thus, in theory, we can have sharper dose gradients using the <u>distal</u> edge than if we use the <u>lateral</u> edge.



But stopping can be dangerous if we don't know where...

Getting it right...



Getting it wrong...



The problem of range uncertainty







Examples of range uncertainty 1 – cavity filling





Planning CT

Repeat CT after 2 weeks

Unavoidable range changes of centimeters...



Examples of range uncertainty 2 - motion



Martijn Engelsmann, MGH (now at HollandPTC)



Examples of range uncertainty 3 - motion



Martijn Engelsmann, MGH (now at HollandPTC)



Why is range uncertainty a problem?

1. (Partial) target misses...



Francesca Albertini and Alessandra Bolsi (PSI)





2. Unplanned cold and hot spots...

3 field IMPT plan



Lomax AJ (2007) in 'Proton and charged particle Radiotherapy', Lippincott, Williams and Wilkins





3. Enlarged volumes to ensure target coverage under conditions of motion



Motion compensated volumes for photons



3. Enlarged volumes to ensure target coverage under conditions of motion



Motion compensated volumes for <u>photons</u>



Motion compensated volumes for protons



Why is range uncertainty a problem?

4. Overdosing (distal) critical structures

The sharpest gradient is only sharp....

...if it stops in the right place





The problem of range uncertainty



But are things always really as bad as they seem?





Things might not be as bad as they seem...

Remember this?



Planning CT



Repeat CT after 2 weeks



But things might not be as bad as they seem...

Estimating the consequences of extreme anatomical changes





Estimating the consequences of extreme anatomical changes



Change in mean dose: +0.7%

Change in max dose: +7.6%

Change in mean dose: +0.0% Change in max dose: +0.1%



Estimating the consequences of extreme anatomical changes



Change in mean dose: +4.6%

Change in max dose: +3%

Change in mean dose: +18.3% Change in max dose: +6.5%



But things might not be as bad as they seem...

(Partially) robust planning





But things might not be as bad as they seem...

And what about this?





Motion compensated volumes for <u>photons</u>

Motion compensated volumes for protons



Photons vs. protons with motion compensated volumes



Bernatowicz et al 2016, Submitted to Strahl. Ther., Oct 2016



The Bragg peak and the SOBP in water





... and what about the ,sharpest' gradient?

But real patients are not water....

Bone ($\rho \approx 1.5$)





... and what about the ,sharpest' gradient?

Density (range) effects on protons

Degradation of the Bragg peak







Density (range) effects on protons



Protons Through Base of Skull: 90 to 20% fall of increases from 6 to 32 mm

Urie et al, PMB, 1986, 31;1-15



... and what about the ,sharpest' gradient?

Density (range) effects on protons



Often, in patient geometries, there are no 'sharp' distal edges



Not the ,sharpest' gradient, but sharp enough...

However, we exploit the Bragg peak in every proton therapy treatment to significantly reduce doses to normal tissues

Large sacral chordoma

SIB treatment to a Parotid tumour



... and in many cases, the advantage will remain, even if there is a certain amount of range uncertainty.



- We should certainly consider and understand the possible effects of range uncertainty
- But we shouldn't be paranoid about it
- Certainly, it is not good practice to stop a single field against a critical organ (e.g. spinal cord)
- But we can (and do!) use the stopping characteristics of protons to spare large volumes of normal tissue with almost every proton treatment we deliver
- Used carefully and sensibly, protons can be a very powerful, and safe, treatment modality <u>despite</u> range uncertainty



The bottom line...

Although the Bragg peak maybe a two edged sword, one edge is still very much sharper than the other...



Skull base tumours 222 Patients 7y Local control: 80%

> Ependymomas 50 Patients 5y Local control: 78%

Parameningeal Rhaddomyosarcomas 31 Patients 5y Local control: 73%

> Sacral chordomas 36 Patients 5y Local control: 66%

